The global prosthetic joint infections treatment market was valued at USD 95.59 Million in 2019 and is projected to reach USD 120.59 Million by 2027, expanding at a CAGR over 2.7% during the forecast period. Prosthetic implantations improve a patient’s quality of life; however, some related complications include aseptic failure and PJI infection. Infections caused by prosthetic joints require the combination of medical and surgical care. Treatments aim at alleviating suffering, restoring functions, and eliminating the infection. Factors need to be considered when selecting an appropriate approach for an individual patient are type of infection, presence of loosening, functional prognosis, etiology, and preferences of the patient. The market is driven by factors such as increasing incidence of road accidents and severe sports injuries and rising incidences of prosthetic joint infection (PJI). This, in turn, is boosting market growth.
Manufacturers are focused on developing innovative drugs for the treatment of PJI and technological advancement and development of innovative treatment options for the treatment of the ailment, which in turn, is propelling the growth of the market. The integration between government reimbursement policies with hospitals & clinics and the launch of innovative products for the treatment of PJI are the key opportunities in this market. Factors restraining the growth of this market include high cost of PJI treatment and lack of trained pathologists for performing the histological analysis.
Rising Incidences of PJI
Prosthetic joint infection or PJI is a serious complication in joint replacement surgeries. It is a major threat in surgeries such as total joint arthroplasty (TJA), knee replacements surgery, and hip replacements surgery. Rise in number of knee replacements and hip replacement surgeries surges the risk of infections, which in turn, is expected to boost the market growth during the forecast period. According to the Orthobullets, Epidemiology of Prosthetic Joint Infection 2020, the incidence rate of infection for primary joint replacement surgeries for total hip arthroplasty (THA) is around 3% and for total knee arthroplasty (TKA) is around 2%. According to same source, the risk of injection for revision joint replacement surgeries is more than primary joint replacement surgeries, the reported risk of infection for THA is around 6%, while that of TKA is around 4%. These factors are projected to boost the prosthetic joints infection treatment market during the forecast period.
Growing Focus of Manufacturers on Developing Innovative Drugs for PJI
Increasing demand for the treatment of prosthetic joint infection has encouraged major players to invest more in research activities to develop new innovative products indicated for treating prosthetic joint infection. Manufacturers are engaged in clinical trials for drug compounds to treat PJI. A few players have succeeded in getting approval from regulatory bodies for clinical trial. For instance, Nabriva Therapeutics plc, has Lefamulin (IV/Oral) compound in Phase I of clinical trial for the indications including STIs, HABP/VABP, Osteomyelitis, and prosthetic joint infection. Moreover, Arrevus have ARV 1801 in the Phase II clinical trial. Whereas, others players including Mellinta therapeutics and Telephus Medical have their compounds under pipeline for the prosthetic joint infection indication. This is expected to drive the market growth in the coming years.
On the basis of treatments, the market has been divided into antibiotics, debridement, and irrigation with implant retention. The debridement segment is expected to hold at substantial market share during the forecast period as debridement consumes less time, is easier to perform than other surgeries, and requires reduced physiologic effects, hastening recovery. The antibiotics segment is anticipated to expand at a CAGR of around 3.6% during the forecast period, as new antibiotics in the market lead to successful outcomes with regards to function and quality of life.
Based on end-user, the market has been bifurcated into hospitals and clinics. The hospital segment is projected to constitute around 63.88% share of market in 2026 at CAGR of approximately 2.9%. The clinical segment is estimated to expand at substantial CAGR of over 2.4% during the forecast period.
On the basis of regions, the global penetrating market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). North America is a key region of the market. It accounted for market share of over 34.55% in 2019. Increase in the acceptance for novel treatments and technological advancements in the US, is expected to boost the demand for PJI treatment in the country during the forecast period. The market in Asia Pacific is estimated to expand at a significant CAGR of around 3.2% due to the increasing awareness regarding PJI treatment.
Some frequently asked quetions about this report!
Additional company profiles can be provided on request.
Yes, the pipeline analysis is available on request.
Yes, the report gives the brief introduction of the types of prosthetic joint infections.
Yes, the report covers product specific information such as antibiotics, debridement, and irrigation with implant retention, etc.
According to this Growth Market Reports report, the market from Prosthetic Joint Infections Treatment is likely to register a CAGR over 2.7% during forecast period 2020-2027, with an anticipated valuation of USD 120.59 million by the end of the 2027.
In addition to market size (in USD Million) and Company Market Share (in % for base year 2019), other data such as Pipeline analysis, Future Perspective: Ambulatory Surgical Centers, and Revision Surgery Outlook. Additionally, the report also has SWOT analysis for companies.
The increasing incidences of road accidents and severe sports injuries, rising incidences of PJI, growing focus of manufacturers on developing innovative drugs for PJI, technological advancements and developments of new innovative treatment option for PJI treatment, increasing focus on brand protection are expected to drive the market growth during forecast period.
Hospitals and Clinics are the key end-user that are driving the prosthetic joint infections treatment market.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
COVID-19 hampered the orthopedic industry. This, in turn, is restraining the prosthetic joint infection treatment market. According to the survey, the risk of taking care of family members suffering from the COVID is high.
The base year considered for the global Prosthetic Joint Infections Treatment market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027.
Major Manufactures include, MELINTA THERAPEUTICS, INC., Nabriva Therapeutics plc, and Arrevus.
Some other reports from this category!